Technical Data
COX 2 (Cyclooxygenase 2, PGHS 2, Prostaglandin Endoperoxide Synthase 2, PHS 2)
Cyclooxygenase (COX) is a membrane-bound enzyme, which has a molecular weight of 71kD. It is an enzyme that catalyzes the synthesis of cyclic endoperoxides from arachidonic acid to form prostaglandins (lipid-soluble, hormone-like regulatory molecules). Two isoforms of COX have been identified and are known as COX-1 and COX-2. COX-2 is dimeric and is the inducible (i.e., sites of inflammation) isoform of cyclooxygenase . It is normally localized to the endoplasmic reticulum and the nuclear envelope. COX-2 is upregulated in response to endotoxins, pro-inflammatory cytokins, growth factors, hormones, and tumor promoters and in carcinomas, including, sporadic colorectal, breast, pancreatic and cervical carcinomas. It is thought that COX-2 has a role in apoptosis, as well as in carcinogenesis. COX-2 is also constitutively expressed in the brain and kidney. COX-2 is normally undetectable in many tissues.

Suitable for use in Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
Immunohistochemistry: Frozen and formalin-fixed, paraffin-embedded tissue sections.
Optimal dilutions to be determined by the researcher.

Recommended Positive Control: Colon carcinoma

Epitope Retrieval: Required (Citrate Buffer, pH 6.0)

Enzyme Digestion: Not Required

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
500ul-20CBlue IceHumanMouse
Synthetic peptide corresponding to human COX-2. Expected Staining Pattern: Cytoplasm.
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.1% sodium azide.
Recognizes human COX-2.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Kaufmann, WE, et al., Proc Natl Acad Sci 93: 2317-2321, 1996. 2. Kim, HJ, et al., Intl J Oncol 22(1): 99-105, 2003. 3. Kulkani, SK, et al., Meth & Findings Exp & Clin Pharm 22(5):291-298, 2000.